DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Cobimetinib and vemurafenib work in patients with these types of cancers which have certain changes in th

Trial Details

NCT ID
NCT05768178
Phase
PHASE2 / PHASE3
Sponsor
Cancer Research UK
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Vemurafenib
  • Cobimetinib
Locations (sample)
  • Belfast, United Kingdom|54.59682,-5.92541
  • Birmingham, United Kingdom|52.48142,-1.89983
  • Bristol, United Kingdom|51.45523,-2.59665
  • Cambridge, United Kingdom|52.2,0.11667
  • Cardiff, United Kingdom|51.48,-3.18

Key Eligibility Criteria

  • Inclusion Criteria:
  • A. Confirmed diagnosis of a malignancy harbouring any actionable BRAF V600 mutation using an analytically validated next-generation sequencing method.
  • B. Adult patients ≥18 years old.
  • C. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patie…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →